Introduction
Pharmacotherapy of Alzheimer's disease (AD) is restricted to symptomatic treatment, and has not been helpful in improving the deterioration of this disease (Tariot and Federoff, 2003) . AD is a neurodegenerative condition that is characterized by progressive neuronal loss. There are many biological and cellular alterations in patients with AD; many aspects are involved in the pathogenesis of AD (Mattson et al., 2001 ).
One of the most convincing hypothesis states that the conditions of AD may be a consequence of the neurotoxic properties of amyloid-β peptides (Aβ), although this hypothesis is still being argued (Naslund et al., 2000; Rottkamp et al., 2002 , Selkoe, 1991 . Aβ is considered to cause progressive synaptic degeneration and neuronal loss, thereby result in cognitive dysfunction and behavioral abnormalities in AD (Stepanichev et al., 2004) . There is also extensive evidence indicating that oxidative stress might be responsible for dysfunction or death of neuronal cells in AD (Butterfield et al., 2002; Markesbery et al., 2001 , Mattson et al., 2001 ). The molecular mechanisms of Aβ toxicity remain unclear. However many studies supported the idea that an oxidative event is critical for Aβ toxicity (Rottkamp et al., 2002) . For example, Aβ toxicity is considered to be caused by unregulated reactive oxygen species such as hydrogen This article has not been copyedited and formatted. The final version may differ from this version. (Barnham et al., 2004) . From this point of view, preventing oxidative stress might protect the remaining neurons from Aβ insult during disease progression.
Neurotrophic factors have been studied as one of the potential future therapies for AD (Tariot and Federoff, 2003) . Neurotrophic factors can support the remaining neurons and protect them against disease progression in animal and cell culture models of neurodegenerative diseases (Mattson et al., 2001 ). In the adult nervous system, neurotrophic factors can also regulate neuronal plasticity by promoting nerve growth following injury (Gillespie, 2003) and thereby promote functional restoration (Lim et al., 2003) . These features suggest that activation of neurotrophic pathways can contribute to the modification and prevention of disease progression in patients with AD.
T-817MA (1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate) is a newly synthesized agent, which was screened as a candidate therapeutic agent for the treatment of AD. Screening was carried out based on the neuroprotective potency against Aβ-induced neurotoxicity and enhancing effect on axonal regeneration in the rat sciatic nerve axotomy model (daily treatment with T-817MA for 14 days enhanced the maximal regeneration distance of sciatic nerve axons measured using an electrophysiological analysis; in house preliminary data), in the expectation of obtaining a neurotrophic agent. In the present study, in order to determine whether T-817MA This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on March 29, 2005 as DOI: 10.1124 at ASPET Journals on July 7, 2017 jpet.aspetjournals.org Downloaded from JPET #83543 -7 -exerts neurotrophic potency on central nervous system (CNS), we evaluated its neuroprotective effect and neurite outgrowth promoting effect. Neuroprotective effect of T-817MA was assessed in Aβ(1-42) or H 2 O 2 -induced neuronal damages by using a coculture of rat cortical neurons with glia. The neurite outgrowth promoting effect was assessed by using a hippocampal slice culture and cultured reaggregates of rat cortical neurons. The therapeutic potential of T-817MA in AD is also discussed.
Materials and Methods

Animals
Pregnant female Wistar/ST rats were purchased from Japan SLC, Inc. (Shizuoka, Japan) and kept in individual aluminum cages with laboratory bedding in an air-conditioned room on a 12h light/dark cycle. The animals were given free access to a commercial diet (MF, Oriental Yeast Co., Ltd. Tokyo, Japan) and water. Neonatal rats were housed with their mother rat. All the experiments were performed in accordance with the Guide for Care and Use of Laboratory Animals at Toyama Chemical Co., Ltd. and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Materials
This article has not been copyedited and formatted. The final version may differ from this version. -9 -Neuron/Glia coculture. We prepared primary cortical neurons plated onto glia monolayer cultures with referring to a previously reported method (Pike et al., 1993) .
Primary cultures of cortical glial cells were prepared from 1-or 2-day-old neonatal rats. (Brooke et al., 1999 Each solution was diluted with 1 ml of distilled water. The absorbance of each reaction solution was measured at 490 nm. All the procedures were performed at room temperature.
Neuroprotective effect against H 2 O 2 -induced toxicity
Assessment in neuron/glia coculture. A cortical neuron/glia coculture was prepared as electrode (RE-100, Eicom). Authentic GSH (Sigma-Aldrich) was simultaneously measured as an external standard under these conditions. Neuronal cell viability was also quantified by measuring the MAP2-immunoreactivity as described above.
Evaluation of Neurite Outgrowth Promoting Effect
Hippocampal slice culture. Organotypic hippocampal slice culture was prepared in accordance with the previously reported method (Stoppini et al., 1991) with some modifications. Hippocampal slices were prepared from 7-day-old rat pups. The dorsal hippocampus was isolated and cut into transverse slices of 350-µm thickness with a tissue chopper (Mickle Laboratory Engineering, Guilford, UK). The slices were placed onto dishes pre-coated with poly-L-lysine (3 slices in each dish) and cultured in interface configuration with DMEM containing 12.5 mM HEPES, 1% (v/v) B-27 Supplement (Invitrogen Corp.) 2 mM glutamine and 25 µg/ml gentamicin sulfate.
T-817MA was added at concentrations of 0 (Control), 0.01, 0.1 and 1 µM at the initiation of the slice culture. The culture was then incubated at 37°C in the 5% CO 2 /95% air for 8 days. During culture period half the volume of the medium in each dish was changed every 2 or 3 days.
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The cortical neurons were harvested from rat embryos (E18). Dissociated cortical cells were suspended in DMEM containing 10% FBS, 2 mM glutamine and 25 mg/ml gentamicin sulfate, and seeded onto 100-mm non-coated dishes at a density of 50,000 cells/mm 2 and then cultured for 4 days. antibody.
Statistical Analysis
The results are represented as mean with S.E.M. Statistical significance of the differences between the two groups was analyzed by an analysis of variance (F-test)
followed by Student's t-test. Statistical significance of the T-817MA-treatment groups from the control group was evaluated by Dunnett test. These analyses were performed by using SAS release 8.2 (SAS Institute Japan Ltd., Tokyo, Japan). P<0.05 (two-tails) was considered to be significant.
Results
Neuroprotective effect of T-817MA
This article has not been copyedited and formatted. The final version may differ from this version. -18 -Control). When T-817MA was pretreated for 24 h, T-817MA significantly prevented this neuronal damage at 0.1 and 1 µM (Fig. 3-A) . On the other hand, a brief (5 min) pre-treatment with T-817MA followed by its continuous presence with H 2 O 2 did not rescue the H 2 O 2 treated neurons from death ( Fig. 3-B ).
T-817MA attenuated H 2 O 2 -induced reduction of intracellular GSH contents.
A similar protective effect of T-817MA was observed in the primary cortical neuron culture. H 2 O 2 exposure at 30 µM for 24 h induced neuronal death (Fig. 4 -A, Control).
Twenty four hours of pre-treatment followed by the continuous presence of T-817MA prevented this oxidative stress-induced neuronal death at 0.1 and 1 µM (Fig. 4-A) . In order to investigate the effect of T-817MA on this oxidative stress, intracellular GSH content was measured as an index of the intracellular oxidative condition in rat cortical neurons under H 2 O 2 exposure. In this experiment, primary cultures of cortical neurons were exposed to 30 µM H 2 O 2 for 4 h. Viability of neurons was not altered at 4 h following 30 µM H 2 O 2 exposure (Fig. 4-B) . On the other hand, GSH content was significantly reduced by this stress (Fig. 4-C (Fig. 4-C) . T-817MA alone did not exert significant effect on the intracellular GSH content in the Normal medium (data not shown).
T-817MA promoted neurite outgrowth
We further investigated the neurite outgrowth promoting action of T-817MA by using two types of cultured neurons, namely the hippocampal slice culture and the cortical reaggregation culture. Hippocampal slices with 1 µM T-817MA treatment generated more and much longer neurites than Control slices (Fig. 5-A, B) . T-817MA significantly increased the neurite length at 0.1 and 1 µM (Fig. 5C ).
Neurite outgrowth promotion of T-817MA was similarly observed in the cortical reaggregation culture. Typical photomicrographs revealed that T-817MA treatment induced reaggregates to generate longer neurites than Control slices (Fig. 6-A, B) .
T-817MA significantly promoted neurite outgrowth at 0.1 and 1 µM (Fig. 6-C) . In addition to the neurite length, we also quantified the immunoreactivity of neurites for GAP-43, which is specifically located in axons. GAP-43 immunoreactivity was significantly increased by T-817MA (Fig. 6-D) . The effect of IGF-1, which has potential to promote neurite outgrowth in vitro (Kim et al., 1997) , was evaluated in this cortical reaggregation culture as a reference experiment. IGF-1 promoted neurite outgrowth:
This article has not been copyedited and formatted. The final version may differ from this version. -20 -GAP-43 immunoreactivity (A 490 nm) was 0.236 with 100 ng/ml IGF-1, which was higher than the Control value (A 490nm: 0.158). This result indicated that the cortical reaggregation culture was useful for assessing neurite outgrowth promotion.
Discussion
AD is a neurodegenerative condition characterized by progressive neuronal loss, which may be a consequence of the neurotoxic properties of the Aβ (Naslund et al., 2000; Selkoe, 1991) . The current treatment with acetylcholinesterase inhibitors focuses on the activation of the remaining functional capacities (Tariot and Federoff, 2003) . Although drugs focusing on neuroprotection have been actively developed recently, causal therapy for such neurodegenerative diseases is unavailable.
T-817MA was screened as a candidate therapeutic agent for AD. The present data indicates that T-817MA exerts a neuroprotective effect and promotes neurite outgrowth in rat primary cultured neurons. Considering these neurotrophic properties, T-817MA would modify or prevent pathological deterioration in AD.
In the present study, we demonstrated that T-817MA exerted neuroprotective effect against (Butterfield et al., 2002; Markesbery et al., 2001 ) and the reduction of endogenous antioxidant processes (Olivieri et al., 2001) . Therefore, in order to understand the neuroprotective effect of T-817MA we focused our interest on oxidative stress-induced cell death.
T-817MA exerted its neuroprotecting effect when the cells were pretreated with T-817MA for 24 h prior to the H 2 O 2 exposure. Unlike antioxidants (Fuson et al., 1999) , T-817MA was unable to protect neurons when it was applied just prior to oxidative stress exposure. Based on this result, it is supposed that T-817MA might exert its neuroprotective effect through the modulation of endogenous anti-oxidative mechanisms, rather than scavenging the reactive oxygen species. In the current study, we employed a neuron/glia coculture because Aβ application failed to induce clear neurotoxicity in the primary culture of the enriched cortical neurons. Previous studies indicated that coexistence of glial cells enhanced Aβ-induced neurotoxicity by modifying the redox status in the neuron/glia coculture (Abramov et al., 2004; Abramov et al., 2003; Qin et al., 2002) . In order to demonstrate that T-817MA interacts with neurons themselves, we also investigated H 2 O 2 -induced neuronal damage in a primary This article has not been copyedited and formatted. The final version may differ from this version. GSH is an important intracellular antioxidant that protects the neurons against a variety of reactive oxygen species (Schulz et al., 2000) . Decrease in GSH was supposed to contribute possibly to signaling events occurring during apoptotic neuronal death (Kane et al., 1993) . Disturbance of GSH homeostasis may either lead to or result from oxidative stress in neurodegenerative disorders, and the treatments that inhibit GSH degradation may result in slowing the disease progression (Schulz et al., 2000) . In our current experiment, the reduction of endogenous antioxidant processes might precede the neuronal damage. In this brief oxidative stress condition, T-817MA attenuated the preceding reduction of the intracellular GSH content, although T-817MA had no effect in the normal condition (data not shown). Based on these results we assumed that T-817MA maintained the intracellular GSH content and resulted in preventing cell death under the oxidative stress condition. In addition, pre-treatment of T-817MA was reactive oxygen species generated from astrocytes (Abramov et al., 2004) , promotion of the antioxidant processes in neurons might also contribute to the neuroprotective effect of T-817MA against Aβ(1-42)-induced neuronal damage in the neuron/glia coculture, although effects of T-817MA on glia cells cannot be excluded. There are many evidences suggesting that oxidative stress might be responsible for dysfunction or death of neuronal cells in AD (Butterfield et al., 2002; Markesbery et al., 2001 , Mattson et al., 2001 ). Oxidative stress in particular has been shown to be one of the earliest changes in disease pathogenesis in AD (Nunomura et al., 2001 ). On these presuppositions the antioxidative effect of T-817MA which may be able to slow down the disease progression in the early stage of AD, would be beneficial for AD treatment.
In the present study, T-817MA significantly increased neurite outgrowth. In order to evaluate neurite outgrowth we utilized an anti-GAP-43 antibody. GAP-43 is expressed in an axon and a growth cone at high levels during periods of axon elongation (Goslin et al., 1998; Meiri et al., 1986; Schereyer et al., 1997) and was reported to be a useful tool In AD, Aβ deposition is considered to cause disruption of the neural network including progressive synaptic degeneration and neuronal loss, which consequently results in cognitive dysfunction and behavioral abnormalities (Stepanichev et al., 2004) . Hence reconstructing the damaged neural network is a possible therapeutic target of the disease.
The neurite projection has the potential to form a target-oriented and active synapse, and subsequently could reproduce functional connections (Li et al., 1994; McKinney et al., 1999; Stoppini et al., 1993) . Therefore promoting neurite outgrowth is supposed to be essential for reconstructing the damaged neural network in AD and various other neurodegenerative diseases. It is reported that some substances, that possess neurite outgrowth promoting effect in vitro are useful in treatment of AD (Gillespie, 2003; O'Neill et al., 2004; Tohda et al., 2004) .
In the present in vitro investigations T-817MA was demonstrated to have both a neuroprotective effect and a neurite outgrowth promoting effect at the same This article has not been copyedited and formatted. The final version may differ from this version. (Mattson et al., 2001) . For example, brain derived neurotrophic factor stimulates the production of various factors, such as antioxidant enzymes and anti-apoptotic protein for protection against oxidative insult relevant to the pathogenesis of AD and other neurodegenerative diseases (Mattson et al., 2001 ). IGF-1 has a well described neuroprotective effect against excitotoxic, metabolic and oxidative insults in various experimental models for AD, and it promotes neurogenesis and synaptic formation throughout the brain and IGF-1 is actively transported across the blood-brain barrier (Heck et al., 1999; Gasparini and Xu, 2003; Mattson et al., 2001; Wei et al., 2002) . Therefore IGF-1 has been indicated as a potential therapeutic target of AD (Gasparini and Xu, 2003) . In spite of these benefits, in general, the therapeutic application of neurotrophic factors themselves to neurodegenerative Normal (Student's t-test). 
Control (Dunnett test).
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